Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 28, 1082-1087, June 1, 1968]
© 1968 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yarbro, J. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yarbro, J. W.

Further Studies on the Mechanism of Action of Hydroxyurea1

J. W. Yarbro

Departments of Medicine and Biochemistry, University of Minnesota Medical Center, Minneapolis, Minnesota 55455

Addition of the four deoxyribonucleosides in vitro to 6C3HED mouse ascites tumor stimulates 32P incorporation into DNA and depresses incorporation into RNA at concentrations greater than 10-4 M. The four ribonucleosides stimulate incorporation into both DNA and RNA. Hydroxyurea blocks the ribonucleoside stimulation of 32P incorporation into DNA but not RNA. The inhibition of 32P incorporation into DNA by hydroxyurea is not prevented by the four deoxyribonucleosides in vitro when added either initially or at intervals throughout the period of incubation. Studies in vivo also indicate the failure of deoxyribonucleosides to prevent inhibition induced by hydroxyurea. The failure of deoxyribonucleosides to prevent the hydroxyurea effect cannot be explained on the basis of the failure of the added nucleosides to be incorporated into DNA or on the basis of their conversion to ribonucleosides and secondary inhibition of DNA synthesis. It would appear, on the basis of these data, that in this system the primary site of action of hydroxyurea is not at the level of conversion of ribonucleotides to deoxyribonucleotides and, therefore, additional sites of action should be investigated.

1 This investigation was supported in part by USPHS Research Grants CA-08344, CA-08832, CA-05862, CA-05158, and CA-08101 from the National Cancer Institute.

Received 9/20/67. Accepted 2/18/68.




This article has been cited by other articles:


Home page
BloodHome page
M. C. Heinrich, K. V. Silvey, S. Stone, A. J. Zigler, D. J. Griffith, M. Montalto, L. Chai, Y. Zhi, and M. E. Hoatlin
Posttranscriptional cell cycle-dependent regulation of human FANCC expression
Blood, June 15, 2000; 95(12): 3970 - 3977.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
N. Uchida, A. M. Friera, D. He, M. J. Reitsma, A. S. Tsukamoto, and I. L. Weissman
Hydroxyurea Can Be Used to Increase Mouse c-kit+Thy-1.1loLin-/loSca-1+ Hematopoietic Cell Number and Frequency in Cell Cycle In Vivo
Blood, December 1, 1997; 90(11): 4354 - 4362.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1968 by the American Association for Cancer Research.